EPEN-46. DNA METHYLATION LANDSCAPE OF RECURRENT PEDIATRIC EPENDYMOMA IDENTIFIES KEY DRIVER EVENTS. (4th December 2020)
- Record Type:
- Journal Article
- Title:
- EPEN-46. DNA METHYLATION LANDSCAPE OF RECURRENT PEDIATRIC EPENDYMOMA IDENTIFIES KEY DRIVER EVENTS. (4th December 2020)
- Main Title:
- EPEN-46. DNA METHYLATION LANDSCAPE OF RECURRENT PEDIATRIC EPENDYMOMA IDENTIFIES KEY DRIVER EVENTS
- Authors:
- Zhao, Sibo
Li, Jia
Zhang, Huiyuan
Qi, Lin
Du, Yuchen
Kogiso, Mari
Braun, Frank
Lindsay, Holly
Genevini, Paola
Veillard, Anne-Clemence
Schvartzman, Sol
Laczik, Miklos
Berguet, Geoffrey
Adesina, Adekunle
Stephan, Clifford
Chintagumpala, Murali
Parsons, Williams
Perlaky, Laszlo
Song, Yongcheng
Sun, Deqiang
Li, Xiao-Nan - Abstract:
- Abstract: Pediatric ependymoma has a propensity of developing late and multiple relapses over many years. About 50% of patients will experience relapses and eventually succumb to their disease. Our study is aimed to understand the mechanism of resistance and drivers associated with pediatric ependymoma relapse. We developed 10 sets of patient-derived orthotopic xenograft (PDOX) models of recurrent pediatric ependymoma from both RELA and PFA tumors. Time from primary tumor to last recurrence ranges from 2.75 – 13 years. Number of recurrences per patient ranges from 1 – 7 times. We performed Reduced Representation Bisulfite Sequencing (RRBS) and Whole Genome Bisulfite Sequencing (WGBS) to map the DNA methylation landscape of total of 30 samples of matched primary and recurrent tumors. Molecular subtypes and DNA methylation profiles were maintained, and RELA/PFA signature genes showed similar expression pattern during serial relapses. RELA- and PFA-specific Differentially Methylated CpGs (DMCs) are identified from primary tumors. During the recurrent process, individual patients displayed consistent changes of DMCs and shared DMCs among patients became convergent. We then identified shared common specific DMCs in recurrent RELA and PFA tumors that emerged as the driver signatures. We found that these recurrent DNA methylation signatures could be identified from primary tumors. Our analysis of the PDOX models showed that they can mostly recapitulate humor tumors' DNA methylationAbstract: Pediatric ependymoma has a propensity of developing late and multiple relapses over many years. About 50% of patients will experience relapses and eventually succumb to their disease. Our study is aimed to understand the mechanism of resistance and drivers associated with pediatric ependymoma relapse. We developed 10 sets of patient-derived orthotopic xenograft (PDOX) models of recurrent pediatric ependymoma from both RELA and PFA tumors. Time from primary tumor to last recurrence ranges from 2.75 – 13 years. Number of recurrences per patient ranges from 1 – 7 times. We performed Reduced Representation Bisulfite Sequencing (RRBS) and Whole Genome Bisulfite Sequencing (WGBS) to map the DNA methylation landscape of total of 30 samples of matched primary and recurrent tumors. Molecular subtypes and DNA methylation profiles were maintained, and RELA/PFA signature genes showed similar expression pattern during serial relapses. RELA- and PFA-specific Differentially Methylated CpGs (DMCs) are identified from primary tumors. During the recurrent process, individual patients displayed consistent changes of DMCs and shared DMCs among patients became convergent. We then identified shared common specific DMCs in recurrent RELA and PFA tumors that emerged as the driver signatures. We found that these recurrent DNA methylation signatures could be identified from primary tumors. Our analysis of the PDOX models showed that they can mostly recapitulate humor tumors' DNA methylation and we were able to identify shared recurrent specific DMCs associated genes in PDOX models. Our comprehensive data is the first of its kind aimed to investigate the epigenetic mechanisms during pediatric ependymoma recurrence. … (more)
- Is Part Of:
- Neuro-oncology. Volume 22(2020)Supplement 3
- Journal:
- Neuro-oncology
- Issue:
- Volume 22(2020)Supplement 3
- Issue Display:
- Volume 22, Issue 3 (2020)
- Year:
- 2020
- Volume:
- 22
- Issue:
- 3
- Issue Sort Value:
- 2020-0022-0003-0000
- Page Start:
- iii317
- Page End:
- iii317
- Publication Date:
- 2020-12-04
- Subjects:
- Brain Neoplasms -- Periodicals
Brain -- Tumors -- Periodicals
Brain -- Cancer -- Periodicals
Nervous system -- Cancer -- Periodicals
616.99481 - Journal URLs:
- http://neuro-oncology.dukejournals.org/ ↗
http://neuro-oncology.oxfordjournals.org/ ↗
http://www.oxfordjournals.org/content?genre=journal&issn=1522-8517 ↗
http://ukcatalogue.oup.com/ ↗ - DOI:
- 10.1093/neuonc/noaa222.180 ↗
- Languages:
- English
- ISSNs:
- 1522-8517
- Deposit Type:
- Legaldeposit
- View Content:
- Available online (eLD content is only available in our Reading Rooms) ↗
- Physical Locations:
- British Library DSC - 6081.288000
British Library DSC - BLDSS-3PM
British Library HMNTS - ELD Digital store - Ingest File:
- 15438.xml